Covered recipient · General Payments record
NADJA N JONES
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$1,937.01
- Reported across 69 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $561.55 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $180.84 | 2 |
| Lilly USA, LLC | $134.96 | 3 |
| Novo Nordisk AS | $75.23 | 4 |
| Exact Sciences Corporation | $48.23 | 2 |
| Inari Medical, Inc. | $39.15 | 1 |
| ABBVIE INC. | $26.14 | 1 |
| PFIZER INC. | $25.31 | 1 |
| Ardelyx, Inc. | $17.16 | 1 |
| Kowa Pharmaceuticals America, Inc. | $14.53 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.14 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104008976 | CMS |
| Ardelyx, Inc. | $17.16 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146687271 | CMS |
| AstraZeneca Pharmaceuticals LP | $55.85 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105220327 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105618573 | CMS |
| Exact Sciences Corporation | $15.58 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114535500 | CMS |
| Exact Sciences Corporation | $32.65 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114535504 | CMS |
| Inari Medical, Inc. | $39.15 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140115376 | CMS |
| Kowa Pharmaceuticals America, Inc. | $14.53 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113467213 | CMS |
| Lilly USA, LLC | $94.32 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135260022 | CMS |
| Lilly USA, LLC | $23.33 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135230998 | CMS |
| Lilly USA, LLC | $17.31 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135260026 | CMS |
| Novo Nordisk Inc | $18.53 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096807263 | CMS |
| Novo Nordisk Inc | $24.20 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096845152 | CMS |
| Novo Nordisk Inc | $15.44 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096655746 | CMS |
| Novo Nordisk Inc | $17.06 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097728203 | CMS |
| PFIZER INC. | $25.31 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132116224 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.